ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kishi, K.
Right arrow Articles by Yoshimura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishi, K.
Right arrow Articles by Yoshimura, K.
Eur Respir J 2004; 24:263-266
Copyright ©ERS Journals Ltd 2004

Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions

K. Kishi1, S. Homma1, S. Sakamoto1, M. Kawabata1, E. Tsuboi1, K. Nakata2 and K. Yoshimura1

1 Dept of Respiratory Medicine, Respiratory Center, Toranomon Hospital, and 2 Dept of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan

CORRESPONDENCE: K. Kishi, Dept of Respiratory Medicine, Respiratory Center, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. Fax: 81 335827068. E-mail: kazumak@toranomon.gr.jp

Keywords: Doxorubicin, lung cancer, malignant pleural effusion, OK-432, pleurodesis

Received: December 12, 2003
Accepted February 29, 2004

Malignant pleural effusion develops frequently in patients with advanced lung cancer. Chemical pleurodesis is the most effective palliative treatment for these patients.

The efficacy of pleurodesis using both OK-432, a preparation of Streptococcus pyogenes, and doxorubicin for 20 patients with cytology-proven malignant pleural effusion associated with lung cancer was evaluated. After complete removal of pleural effusion, OK-432 and 30 mg of doxorubicin were injected via an inserted chest tube. Treatment was terminated when the volume of daily drainage reached <200 mL. If the daily volume remained >200 mL, an additional OK-432 was administered every 3 days.

In total, 16 patients (80%) revealed a complete response, two patients (10%) revealed a partial response, and no response was seen in two patients. Eighteen patients with complete or partial responses did not show subsequent reaccumulation of pleural effusion after pleurodesis. The chest tube remained in place for an average of 6.4 days, draining a mean of 2,854 mL. The main side-effects were fever and pain that were easily treated with nonsteroidal anti-inflammatory drugs.

Pleurodesis using both OK-432 and doxorubicin showed high efficacy for controlling malignant pleural effusions caused by lung cancer.




This article has been cited by other articles:


Home page
 ThoraxHome page
H. E Davies, Y C G. Lee, and R. J O Davies
Pleurodesis for malignant pleural effusion: talc, toxicity and where next?
Thorax, July 1, 2008; 63(7): 572 - 574.
[Full Text] [PDF]

Home page
 ICVTSHome page
T. Laisaar, V. Palmiste, T. Vooder, and T. Umbleja
Life expectancy of patients with malignant pleural effusion treated with video-assisted thoracoscopic talc pleurodesis
Interactive CardioVascular and Thoracic Surgery, June 1, 2006; 5(3): 307 - 310.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
O. Dikensoy, Z. Zhu, E. Donnelly, G. T. Stathopoulos, K. B. Lane, and R. W. Light
Combination Therapy With Intrapleural Doxycycline and Talc in Reduced Doses Is Effective in Producing Pleurodesis in Rabbits
Chest, November 1, 2005; 128(5): 3735 - 3742.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the European Respiratory Society.